Send to

Choose Destination
See comment in PubMed Commons below
Pancreas. 2014 Apr;43(3):367-72. doi: 10.1097/MPA.0000000000000033.

Can long-term follow-up strategies be determined using a nomogram-based prediction model of malignancy among intraductal papillary mucinous neoplasms of the pancreas?

Author information

From the Departments of *Gastroenterology, and †Gastrointestinal Surgery, Aichi Cancer Center Hospital, Nagoya, Japan; ‡Department of Tropical Medicine and Gastroenterology, Assiut University Hospital, Assiut, Egypt; §Department of Medical Hepatology, Institute of Liver and Biliary Sciences, Delhi, India; and ∥Department of Endoscopy, Aichi Cancer Center Hospital, Nagoya, Japan.



This study investigated whether a risk assessment nomogram can predict the malignant potential of intraductal papillary mucinous neoplasms (IPMNs) and provide valuable information for the follow-up and counseling strategies of such patients.


We studied 126 of 589 patients with IPMN who were followed up for at least 36 months with annual endoscopic ultrasonography. We analyzed scores derived from our nomogram, incorporating the parameters of sex, lesion type, mural nodule height, and pancreatic juice cytology determined at the initial IPMN evaluation.


The rate of malignant IPMNs was 5.5% (7/126). The initial average nomogram score was 19.8 (range, 0-55), and the final follow-up average was 23.8 (range, 0-109). When a cutoff score was set at 35 points, the sensitivity, specificity, and accuracy of the nomogram to assess malignancy risk were 87.5%, 96.6%, and 96%, respectively. The area under the receiver operating characteristic curve of malignant IPMN prediction during follow-up was 0.865.


The ability of the nomogram to predict malignancy in patients with IPMN was validated. Our findings can suggest that a follow-up for patients at high and low risk for cancer progression could be scheduled every 3 to 6 and 12 months, respectively.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Support Center